

From: [Annalise Beube](#)
To: [Mark Taylor](#)
Subject: FW: [EXTERNAL] Unknown Reference Numbers and Acknowledgement Letters
Date: Wednesday, February 11, 2026 1:02:35 PM

See below re FDA.

Annalise Beube, Law Clerk

[Siri | Glimstad](#)

Main: 240-RECORDS

Facsimile: 646-417-5967

20200 West Dixie Highway, Suite 902

Aventura, FL 33180

www.sirillp.com

This email may contain material that is confidential, privileged and/or attorney work product for the sole use of the intended recipient. Any review, reliance or distribution by others or forwarding without express permission is strictly prohibited. If you are not the intended recipient, please contact the sender and delete all copies.

From: FDA FOIA <FDAFOIA@fda.hhs.gov>
Sent: Monday, November 24, 2025 2:13 PM
To: S&G Information Request Staff <foia@sirillp.com>; fda_foi@fda.gov
Subject: Re: [EXTERNAL] Unknown Reference Numbers and Acknowledgement Letters

Good morning,

At this time there is no public facing version of our tracking system.

C.

Charis Wilson, PhD, CRM

Denials and Appeals Officer

Office of Operations | Office of Management and Enterprise Services

U.S. Food and Drug Administration

U.S. Department of Health & Human Services

From: S&G Information Request Staff <foia@sirillp.com>

Sent: Monday, November 24, 2025 11:35 AM

To: FDA FOIA <FDAFOIA@fda.hhs.gov>; S&G Information Request Staff <foia@sirillp.com>;
fda_foi@fda.gov <fda_foi@fda.gov>

Subject: RE: [EXTERNAL] Unknown Reference Numbers and Acknowledgement Letters

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Good afternoon,

Is there a way for me to access FDA's portal to view the requests we submitted, the reference numbers assigned, the date received, and the estimated date of completion?

Annalise Beube, Law Clerk

Siri | Glimstad

Main: 240-RECORDS

Facsimile: 646-417-5967

20200 West Dixie Highway, Suite 902

Aventura, FL 33180

www.sirillp.com

This email may contain material that is confidential, privileged and/or attorney work product for the sole use of the intended recipient. Any review, reliance or distribution by others or forwarding without express permission is strictly prohibited. If you are not the intended recipient, please contact the sender and delete all copies.
